German Merck hints at M&A across divisions

"Considering its recent past, any progress would be an improvement," FierceBiotech's Damian Garde writes, referring to comments made by Merck KGaA (MKGAF) CEO Karl-Ludwig Kley which seem to indicate that the German drugmaker is open to acquisitions across its four business units.

"We have four sustainable business divisions that are set to grow organically, but for all four areas we have ideas for steps that go beyond that," Kley tells the media.

Garde notes that "repeated clinical failures" have left analysts jaded, but innovative ideas like development program cost-sharing could brighten the Erbitux maker's outlook even in the midst of "an R&D diet."

See also: German Merck lifts guidance.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs